OTCMKTS:MLXSF Melexis (MLXSF) Stock Price, News & Analysis → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free MLXSF Stock Alerts $110.65 0.00 (0.00%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$110.65▼$110.6550-Day Range$110.65▼$110.6552-Week Range$100.86▼$110.80VolumeN/AAverage Volume150 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Melexis alerts: Email Address Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. About Melexis Stock (OTCMKTS:MLXSF)Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, current, latch and switch, inductive position, speed, pressure, tire monitoring, temperature, and optical sensors ICs and time-of-flight; embedded motor, smart, fan and pump, smart LED, and pre-driver ICs; embedded lighting; and LIN transceiver, CAN transceiver, and RFID transceivers. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.Read More MLXSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLXSF Stock News HeadlinesApril 24, 2024 | msn.comMelexis Nv Ieper reports Q1 resultsApril 24, 2024 | globenewswire.comMelexis Q1 2024 results – First quarter sales of 241.8 million EURMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.April 23, 2024 | markets.businessinsider.comMelexis Microelectronic Integrated Systems is about to announce its earnings — here's what to expectFebruary 21, 2024 | bbc.co.ukSliced BreadFebruary 7, 2024 | uk.finance.yahoo.comMelexis Q4 and FY 2023 results – Full year sales of 964.3 million EURFebruary 7, 2024 | markets.businessinsider.comHere's what to expect from Melexis Microelectronic Integrated Systems's earningsJanuary 23, 2024 | thetimes.co.ukHousing is at the heart of the financial squeeze families are facingMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.January 23, 2024 | sfgate.com'Affordable' in SF: The lowest priced homes on the market this weekNovember 20, 2023 | finance.yahoo.comMelexis Transparency NotificationNovember 14, 2023 | finance.yahoo.comChanges to the Shareholding StructureNovember 1, 2023 | morningstar.comStifel Financial Corp SFOctober 25, 2023 | uk.finance.yahoo.comMelexis Q3 2023 results – Third quarter sales of 248.6 million EURAugust 19, 2023 | sfgate.comThese businesses are taking a chance on downtown SF despite 'doom loop'August 18, 2023 | sfgate.comA family of four, a beloved uncle and his best friend. These are some of the lives lost in MauiAugust 2, 2023 | msn.comMelexis Nv GAAP EPS of Є1.28, revenue of Є236.65MJune 23, 2023 | sfgate.comEverything to know about Christopher Nolan’s new 'Oppenheimer' movieApril 27, 2023 | uk.finance.yahoo.comMelexis Q1 2023 results – First quarter sales of 228.6 million EURApril 23, 2023 | msn.comMelexis (EBR:MELE) Price Target Increased by 18.54% to 99.68March 29, 2023 | morningstar.comMelexis Should Benefit From Growing Auto Chip Content for YearsFebruary 1, 2023 | uk.finance.yahoo.comMelexis Q4 and FY 2022 results – Full year sales of 836.2 million EUROctober 26, 2022 | uk.finance.yahoo.comMelexis Q3 2022 results – Third quarter sales of 219.8 million EUROctober 16, 2022 | finance.yahoo.comMelexis NV (MLXSF)October 4, 2022 | benzinga.comMelexis Stock (OTC:MLXSF), DividendsSeptember 30, 2022 | reuters.comMLXS.BR - Melexis NV | Stock Price & Latest News | ReutersJuly 29, 2022 | seekingalpha.comMelexis NV (MLXSF) CEO Marc Biron on Q2 2022 Results - Earnings Call TranscriptSee More Headlines Receive MLXSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Melexis and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorComputer and Technology Industry Semiconductors Sub-IndustryN/A Current SymbolOTCMKTS:MLXSF CUSIPN/A CIKN/A Webwww.melexis.com Phone32-5-722-61-31FaxN/AEmployees1,939Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Marc Biron (Age 54)MD, CEO & Director Comp: $510.61kMs. Karen Van Griensven (Age 54)Chief Financial Officer Ms. Veerle Lozie (Age 50)Chief Operations & Information Officer Valerie KerfsInvestor Relations ProfessionalMr. Vincent Hiligsmann (Age 53)Vice President of Corporate Strategy - Global Sales, Brand & Communication Key CompetitorsAlphawave IP GroupOTCMKTS:AWEVFams-OSRAMOTCMKTS:AUKUFDynex PowerOTCMKTS:DNXWFHua Hong SemiconductorOTCMKTS:HHUSFInfineon TechnologiesOTCMKTS:IFNNFView All Competitors MLXSF Stock Analysis - Frequently Asked Questions Should I buy or sell Melexis stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Melexis in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MLXSF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MLXSF, but not buy additional shares or sell existing shares. View MLXSF analyst ratings or view top-rated stocks. How have MLXSF shares performed in 2024? Melexis' stock was trading at $110.65 on January 1st, 2024. Since then, MLXSF shares have increased by 0.0% and is now trading at $110.65. View the best growth stocks for 2024 here. How do I buy shares of Melexis? Shares of MLXSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MLXSF) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melexis NV Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
